AX-2024-005193 · Kisspeptin-10 · CPC lot CPC-2411-W9644

Section 1

Results

Measured against the index acceptance specification for the melanocortin-receptor peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 15 min gradient, 214 nm	99.53	% area	≥ 98.5	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.47	% area	≤ 1.5	PASS
Largest single impurity	RP-HPLC — [D-Trp]-epimer	0.26	% area	≤ 1.00	PASS
Identity	not ordered on this submission	not determined	—	required for VERIFIED status	NOT TESTED
Total peptide content	by difference from the gravimetric mass balance	91.06	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	90.63	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	5.81	mg	5 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	5.266	mg	5 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	105.3	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	3.93	%	≤ 8.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	4.21	%	≤ 10.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.80	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	membrane filtration, USP <71>, 14 d	No growth at 14 d	—	no growth	PASS
Appearance	visual, diffuse light, black and white background	White to pale-yellow cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear with a single visible fibre	—	clear, no visible particulates	FAIL
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	5.06	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 15 min gradient	4.06	min	4.94 ± 0.25 (normalised)	FAIL
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.03	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	57,222	—	≥ 20,000	PASS
Resolution to nearest impurity	vs [D-Trp]-epimer	0.86	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 15 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 57,222, and skew follows the reported asymmetry factor of 1.03. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.26 % impurity against a 99.53 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Kisspeptin-10 — main peak	4.06	4,837,467	99.53	—
2	[D-Trp]-epimer	4.00	12,637	0.26	0.000
3	C-terminal free acid (+1 Da)	4.15	4,374	0.09	+0.984
4	oxidised Trp (+16 Da)	3.89	3,888	0.08	+15.995
5	des-Tyr (−163 Da)	3.78	1,944	0.04	-163.063
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	3.93
Counter-ion (acetate)	ion chromatography	4.21
Residual solvent + inorganic residue	estimated	0.80
Total peptide content	by difference	91.06
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.15	99.53	divergence +0.49 pp vs batch median
Total impurities (% area)	0.85	0.47
Largest single impurity (% area)	0.57	0.26
Water (%)	not stated	3.93
Counter-ion (%)	not stated	4.21
Peptide content (%w/w)	not stated	91.06
Endotoxin (EU/mg)	0.73	not determined
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (ambient, 24 d) → laboratory (courier, cold pack, 4 d) → assay.
Assay date: 26 Nov 2024
Submitted to the index: 28 Nov 2024
Laboratory: Kestrel Bioanalytical, Melbourne, Australia
Method basis: 15 min gradient · unit-resolution MS
Verification status: METHOD LIMITED

What this report does not establish

That the compound is the compound named. No identity confirmation was ordered on this submission. A purity figure describes chromatographic homogeneity of whatever eluted; it does not name it.
That mass-identical impurities are absent. The gradient used is shorter than the index reference method and does not resolve the diastereomers named in the compound fingerprint. The purity figure is an upper bound.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 4

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

prep_hplc_cut28 Nov 2024

0.47 % total impurities on Kisspeptin-10 means the preparative fraction was cut narrow. That trades yield for purity, and the trade was made in the buyer's favour on this lot.

cleavage_cocktail28 Nov 2024

Alkylation artefacts from a scavenger-poor cleavage would appear as a +58 or +76 family here. Absent, which says the cleavage was run properly.

price_per_mg28 Nov 2024

The index cannot verify that the vial assayed is representative of the lot it came from, and says so on every record. Provenance narrows that gap; it does not close it.

plate_count28 Nov 2024

Efficiency is the lever that does not change selectivity, so it improves resolution without moving anything else. Longer column, smaller particle, or lower flow, in that order of cost.

Section 7

Related records

Same batch — lot CPC-2411-W9644 n=8

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2024-005188	CPC-2411-W9644	PeptideMeter	2024-Q4	99.28	4.10	—	Supplier-supplied	PASS
AX-2024-005189	CPC-2411-W9644	Janoshik	2024-Q4	98.70	3.73	—	Buyer-sourced	PASS
AX-2024-005190	CPC-2411-W9644	Janoshik	2024-Q4	98.60	3.69	—	Buyer-sourced	PASS
AX-2024-005191	CPC-2411-W9644	Janoshik	2024-Q4	98.37	3.82	100.4	Buyer-sourced	FAIL
AX-2024-005192	CPC-2411-W9644	Janoshik	2024-Q4	98.76	3.76	—	Buyer-sourced	PASS
AX-2025-020793	CPC-2411-W9644	Nordanalyt	2024-Q4	98.62	3.73	91.8	Buyer-sourced	PASS
AX-2024-005194	CPC-2411-W9644	Nordanalyt	2024-Q4	98.55	3.84	99.4	Buyer-sourced	PASS

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Kisspeptin-10 records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043179	GL Biochem	GLBI-2608-N7715	Medutest	2026-Q3	98.97	4.37	—	Buyer-sourced	1	MARGINAL
AX-2026-043178	GL Biochem	GLBI-2608-N7715	Janoshik	2026-Q3	98.50	4.55	—	Buyer-sourced	1	MARGINAL
AX-2026-043184	GL Biochem	GLBI-2608-N7715	Janoshik	2026-Q3	98.99	3.63	100.6	Supplier-supplied	1	MARGINAL
AX-2026-043185	GL Biochem	GLBI-2608-N7715	Medutest	2026-Q3	98.71	3.71	107.0	Buyer-sourced	1	MARGINAL
AX-2026-043182	GL Biochem	GLBI-2608-N7715	Janoshik	2026-Q3	98.93	3.86	95.7	Buyer-sourced	1	MARGINAL
AX-2026-043183	GL Biochem	GLBI-2608-N7715	PeptideMeter	2026-Q3	98.54	4.17	102.2	Buyer-sourced	1	MARGINAL
AX-2026-043186	GL Biochem	GLBI-2608-N7715	Janoshik	2026-Q3	98.56	3.60	96.8	Buyer-sourced	1	MARGINAL
AX-2026-043181	GL Biochem	GLBI-2608-N7715	Janoshik	2026-Q3	98.77	4.06	95.2	Buyer-sourced	1	MARGINAL

Other recent CPC records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043319	BPC-157	CPC-2602-W1610	Medutest	2026-Q3	98.82	2.88	103.5	Buyer-sourced	2	MARGINAL
AX-2026-043295	Liraglutide	CPC-2602-G9942	Janoshik	2026-Q3	97.34	5.17	106.3	Buyer-sourced	0	FAIL
AX-2026-043288	Tirzepatide	CPC-2607-L1516	Janoshik	2026-Q3	96.89	5.11	101.1	Laboratory-retained	0	FAIL
AX-2026-043327	N-Acetyl Semax Amide	CPC-2602-D1905	Nordanalyt	2026-Q3	99.05	5.67	90.6	Buyer-sourced	1	FAIL
AX-2026-043328	N-Acetyl Semax Amide	CPC-2602-D1905	Janoshik	2026-Q3	99.49	6.83	100.9	Supplier-supplied	0	PASS
AX-2026-043257	L-Carnosine	CPC-2603-G9615	VendorInvestigate	2026-Q3	98.20	10.41	102.2	Buyer-sourced	0	FAIL
AX-2026-043297	Liraglutide	CPC-2602-G9942	Janoshik	2026-Q3	97.01	4.95	103.5	Buyer-sourced	0	FAIL
AX-2026-043331	N-Acetyl Semax Amide	CPC-2602-D1905	Janoshik	2026-Q3	99.46	6.22	—	Supplier-supplied	0	PASS